BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/10/2025 8:40:04 AM | Browse: 71 | Download: 518
 |
Received |
|
2024-08-30 09:38 |
|
Peer-Review Started |
|
2024-08-30 09:38 |
|
First Decision by Editorial Office Director |
|
2024-11-23 05:30 |
|
Return for Revision |
|
2024-11-23 05:30 |
|
Revised |
|
2024-12-07 04:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-20 03:07 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-20 05:59 |
|
Articles in Press |
|
2024-12-20 05:59 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-12-31 00:55 |
|
Publish the Manuscript Online |
|
2025-01-10 08:40 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Editorial |
| Article Title |
Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Wei Luo, Ai-Long Huang and Kai-Fu Tang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China (General Program) |
82172915 |
| National Natural Science Foundation of China (General Program) |
81972648 |
| National Natural Science Foundation of China (General Program) |
81773011 |
| Chongqing Medical University Program for Youth Innovation in Future Medicine |
W0084 |
| Science and Technology Innovation Project of Chongqing Medical Unisversity |
|
| Chongqing Postdoctoral Science Foundation |
CSTB2023NSCQ-BHX0134 |
|
| Corresponding Author |
Kai-Fu Tang, PhD, Professor, Key Laboratory of Molecular Biology on Infectious Disease, Ministry of Education, Chongqing Medical University, No. 1 Yixueyuan Road, Yuzhong District, Chongqing 40016, China. tangkaifu@cqmu.edu.cn |
| Key Words |
Hepatic angiotensin-converting enzyme 2; SARS-CoV-2; Liver infection; Chronic liver diseases; COVID-19 treatment |
| Core Tip |
Angiotensin-converting enzyme 2 (ACE2) serves as the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Jacobs et al discovered that elevated hepatic ACE2 expression during metabolic dysfunction may facilitate SARS-CoV-2 infection, which could potentially exacerbate the severity of coronavirus disease 2019 (COVID-19), suggesting ACE2 as a promising therapeutic target for COVID-19. |
| Publish Date |
2025-01-10 08:40 |
| Citation |
Luo YW, Huang AL, Tang KF. Angiotensin-converting enzyme 2 and hepatic SARS-CoV-2 infection: Regulation, association, and therapeutic implications. World J Gastroenterol 2025; 31(6): 100864 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i6/100864.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i6.100864 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
